Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Collaborates with Euro Sample Banks on Pre-Diabetes Dx

NEW YORK (GenomeWeb News) – Metabolon will collaborate with a group of European research centers to find biomarkers that are related to insulin resistance in an effort to develop a test that could detect diabetes before an individual has the disease.
 
Under the collaboration, Metabolon said it will discover and validate biomarkers from samples collected from studies conducted at 19 different clinical research centers that are members of the European Group for the Study of Insulin Resistance.
 
Insulin resistance generally is an asymptomatic condition that can precede the arrival of type 2 diabetes, and it is estimated to affect around one-third of the adult population in the US, or around 75 million people, the company said. 
 
The company plans to use the research to speed up development of its Quantose test for screening of pre-diabetic patients.
 
Metabolon CEO John Ryals said the “routine test will help identify pre-diabetic patients years before they become diabetic,” and that it could be used to help doctors “intervene with lifestyle or drug therapies which may delay or prevent the onset of type 2 diabetes.”
 
Financial terms of the collaboration were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.